Helen E. Remotti, MD

Board Certifications: 
Pathology-Anatomic/Pathology-Clinical
Accepting New Patients
Profile Headshot

Overview

I joined the division of Surgical Pathology in the Department of Pathology and Cell Biology at Columbia University as a faculty member in 2002. One of my primary functions as a surgical pathologist at Columbia University involves providing diagnostic expertise in diverse areas of pathology from clinical cases with a high level of complexity. I serve as a senior consultant pathologist, with a focused interest in pancreatic, hepatic and gastrointestinal pathology. At Columbia University this subspecialty includes a wide spectrum of diagnostically challenging cases encompassing transplant pathology (liver, small intestine, pancreas), adult and pediatric medical liver disease, and oncologic pathology.

As a member in the division of Personalized Genomics as of 2016, I have been involved in molecular profiling studies examining a variety of types of pediatric hepatobiliary and gastrointestinal tumors. Since 2014, I have been involved in the Precision in Pediatrics (PIPseq) Cancer initiative, and have been working closely with members in the Division of Pediatric Hematology/ Oncology, primarily focusing on molecular studies involving pediatric liver tumors and neuroblastomas. Due to the expertise of our liver surgeons and orthotopic liver transplantation program, and our pediatric oncologists we see an over representation of high risk pediatric hepatic tumors. In collaboration with the Herbert Irving Cancer Center Tumor bank, for these studies we have an established a hepatic tumor pathology database with tissue microarrays and examined a variety of immunohistochemical and molecular biomarkers in subsets of these tumors. These studies may offer patients the possibility of entry into clinical trials that will enable the use of novel targeted drug therapies, particularly in classes of tumors unresponsive to conventional treatment modalities.

Email: her2007@cumc.columbia.edu

Areas of Expertise / Conditions Treated

  • Liver Pathology

Academic Appointments

  • Associate Professor of Pathology & Cell Biology at CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Female

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, Northwestern University Feinberg School of Medicine
  • Residency: University of California Los Angeles Medical Center
  • Fellowship: Armed Forces Institute

Board Certifications

  • Pathology-Anatomic/Pathology-Clinical

Research

Grants

THE DEVELOPMENT AND PROGRESSION OF IPMN TO PDA IN THE CONTEXT OF INACTIVATED ACTIVIN SIGNALING (Federal Gov)

Mar 15 2017 - Feb 28 2022

PH1 STUDY OF T-VEC GIVEN ENDOSCOPICALLY FOR ADVANCED PANCREATIC CANCER IN 17248 (11/21/2016) (Federal Gov)

Aug 1 2018 - Jul 31 2021

THE ROLE OF WILD-TYPE KRAS IN THE CONTEXT OF TUMOR PROGRESSION AND METASTASIS (Federal Gov)

May 1 2015 - Apr 30 2020

THE SAFETY OF RED BLOOD CELL TRANSFUSIONS (Federal Gov)

Jul 1 2014 - Dec 31 2018

DEFINING BIOMARKERS OF IMMUNE ACTIVATION DURING ANTI-PD1+TVEC THERAPY (Private)

Sep 16 2015 - Sep 15 2018

THE SAFETY OF RED BLOOD CELL TRANSFUSIONS (Federal Gov)

Sep 1 2014 - May 31 2018

MOUSE MODEL FOR HUMAN PANCREATIC DUCTAL ADENOCARCINOMA (Federal Gov)

Sep 1 2004 - Mar 31 2017

ROLE OF NEURONS IN THE DEVELOPMENT AND PROGRESSION OF PANCREATIC CANCER (Private)

Jan 1 2013 - Dec 31 2016

HUMAN ISLET ANTGEN DISCOVERY AND IMAGING (Federal Gov)

Jul 6 2009 - May 31 2015